Theratechnologies Inc T.TH

Questions

[StableGenius97]

We out here showing cancer efficacy in cancer and we out here talking about egrifta. Not the game. Egrifta. We talking about egrifta

[qwerty22]

Why isn't oncology front and centre. Feels like they couldn't down play oncology any more than they did.  

[Bucknelly21]

Product of poor coverage 

[qwerty22]

Seems to me they were quite defensive over oncology. I'm wondering if they are concerned that with 18 enrolled and only one clear PR that this data will be seen negatively. For me this update is pretty good. The only real downside is it came 6 months late. It is blown away data but they hit everything they needed to hit. I guess they are looking forward to a sizeable data set coming out

[SPCEO1]

Different people hear things differently. I did not sense any defensiveness. Christian seemed pretty pleased with the results and was happy to share the details. To get any results on efficacy at all in this trial is good. He also mentioned one tumr completely vanished  in the person who saw the 53% reduction, so I am assuming that was not one of the targetted tumors they were focused on. I

[Bucknelly21]

Kinda find some on this board funny, been waiting for poc and an efficacy signal, we get it finally and its not good enough lol 

[SPCEO1]

From a practical perspective, we have POC and indications the drug works. from a scientific perspective, neither has yet been achieved. So the scientists are not going to be satisfied until it is, as they should not be. But we can take away from today's news that we will likely get the scientific proof needed before too much longer. 

[qwerty22]

I think the 53% PR is POC practically and scientifically. It's never 100% but it's hard to ascribe a solid response like that to anything other than the drug. There is some free docetaxel floating around which could account for it. Maybe that could be the cause but Christain did say that patient failed docetaxel treatment recently after 4 cycles. I think what we can see is they are always

[juniper88]

From what I have seen is that we have POC for TH1901. I spoke with Christian a few times in the last couple of years. I asked him, we believe TH1902 can overcome MDR1 but what about the other resistance mechanism? He told me that they didn't know. Now that you have POC of TH1901 you can move on to more toxic bombs that you know will overcome the other resistance mechanisms. In my opinion, this

[jeffm34]

That is my thinking as well. There appears to be enough data available now to garner some serious inquiries.  I don't think the share price will really move until there is validation in TH-1902 from a major pharma 

[qwerty22]

What they've shown is anti-tumour activity. What they next need to show is a particular cancer indication in which the drug can make a meaningful impact on a population. The first step on that road I think is getting at least 2 responders in at least one of the cancer indications in the basket trial. That's not necessarily what partners will wait for but it's the next major derisking.

[Wino115]

They described what you say is the next derisking point, so that's in their sights too. They passed on my sortilin/efficacy question so I think they don't really know that yet as it's very complex since we know actually measuring sortilin is not easy other than the staining for low/mid/high. On the free docetaxal, I think the fact one patient failed two types of taxol treatments but

[jeffm34]

If they choose to do a partnership this early they could give the company the option of selecting one cancer indication within a certain time frame. That way there is incentive to be the first partner, they get to choose their indication. 

[Lldks1]

From a looong time follower and first time poster - could the " not good enough" be that we've been waiting for this ( great?) news yet the share price ( and analysts attention) is meh????

[Wino115]

What analysts (lol)? Yes -- not one serious biotech or cancer analyst covers the stock.  They are marginal tiny firms with zero following in the US.  Guarantee you there is not one new PM looking at THTX this morning because of this.  They need to rebuild that audience, get on to CNBC and get a bit of PR push around this in the general and business press and then, maybe, there's

[qwerty22]

SORT1, a brand new cancer target get's it's first ever human response. If you want to push this it writes it's own headlines. They've done a lot to validate Sortilin and prove out the body of scientific literature that said it had potential. Quebec/Canada news should be all over this. If they understand the achievement here. There's a lot to cheer from a News perspective.

[SPCEO1]

Welcome to the board! I would like to try and answer your question but could you rephrase it for me as I am not sure exactly what you are asking. 

[SPCEO1]

Well that is good to hear. But if so, why not shout that from the mountain top??? I will ask them about that when I have a chance.

[qwerty22]

Yep that was worrying me. Why not shout proof of efficacy in the title of the PR? My best explanation is the free docetaxel offering some nagging doubt about making definitive statements. I think they have a lot of integrity. If they were to say proof of concept they'd probably need to draw attention to some caveats, one of those being free docetaxel. You probably then are deep into the

[Wino115]

My read on the perceived defensiveness is the opposite. I thought both Paul and Christian wanted to keep pointing out that they achieved these results on unbelievably hard to treat patients nearing death and not remotely considered for the actual target.  I thought it was a way to politely push the analysts asking all those unimportant questions to say, "guys, we achieved some darn good

[LouisW]

One one clear PR in 18 patients...that would be interesting if they disclose the SORT expression level in those patients.

[SPCEO1]

I am not sure the sort expression levels were even measured in the 1a.

[Wino115]

I asked the question of explaining whatever they've learned about the correlation of SORT1 and response.  I'm guessing it's rather complicated to measure and figure out and that's part of the ongoing data analysis the researchers are doing and will be released with the full data set and presentation or article from the lead. 

[palinc2000]

 Only 2 of the 18 patients in Phase 1a remain in the trial...Do we assume that most of the 16 did not survive long enough?

[SPCEO1]

Two patients therefore rolled into the phase 1 out of a total of six possible. One patient who has had three cycles of treatment at 300mg was mentioned. If they have seen a partial response, we should know that pretty soon as their 12 week mark is coming up. 

[qwerty22]

One problem is they are essentially still cherry-picking what they want us to know. The 1a data would need to go to a conference poster to get the full picture. Christain was talking about patients choosing to drop out to get back to normal life. Interesting Juniper thought the burden of clinic visits was high with this trial. Must be disease progression and general frailty as an issue too. He

[SPCEO1]

Paul mentioned that there will not be a published evaluation of the trial until early 2023, if I heard him correctly, and that presumably would include phase 1b as well as phase 1a.  They defintely cherry-picked the info they shared with us but the important point remains the same - the drug worked as expected on some patients. That is the first time the company has stated that/. We do not

[jeffm34]

That published evaluation will be for phase 1a only. Phase 1b will still be ongoing well into 2023.  Final readout for that portion would be 2024 at the earliest

[SPCEO1]

Yeah, you must be correct on that. I will check the transcript when it becoes available to s ee what Paul actually said, but your take has to be the correct one.

[qwerty22]

There's going to be overlapping data coming out from this point forward. Interim 1b likely comes before 1a publication. The full 1a data set might not matter all that much by the time it comes out if they have larger and clearer 1b data emerging on safety and efficacy. I guess when I first mentioned poster publication it was imagining something coming out for the Fall conference season in

[SPCEO1]

Remember Christian mentioned to me that they might have soething to present at the AACR conference, which we think he was referring to one in October. If that were true, then he must be assuming some quick success in phase 1b and a late breaker presentation. But I am not 100% sure if it true. Key points from today: 1.) POC has been achieved. The drug has been significantly derisked 2.) The drug

[Wino115]

Concur, and if they proactively start pushing themselves in front of firms and analysts that can understand what this all means around the risks/opportunities and rapid timeline and get the scientific nuance and data they talk about, it really should bring in new investors and continue driving the share price and hopefully a new high with a 5-7 handle!   But it's a big "if" that

[qwerty22]

"I am not sure what you think is unclear."   I was trying to give my best answer to Palinc Q about whether we assume the other 16 did not survive long enough. That seems unclear. Christian gave a number of potential reasons why people might have dropped out. Sometimes contradictory (which doesn't matter too much in this context). It's unclear why people dropped out

[SPCEO1]

Based on what I have come to know about these trials, the human factor is a big deal. Like the person who just wanted to return to a normal life after 33 weeks on the trial. Rationally, that person would have stayed on the trial as long as possible but the effort involved and the many twists and turns this person likely had already faced can easily wipe you out both physically and emotionally

[qwerty22]

You have to understand SD is a veryspecific description of how their tumours are responding not how they feel. It doesn't tell you anything about their general health. They may not have been experiencing this effect as any sort of improvement in the quality of their life. While SD is something for trial sponsors it might not match the expectations of the patient. 

[Wino115]

Yes. They used polite words to convey that, but it seems pretty clear these patients were literally at the very end having had on average 8 attempted treatments, some of which probably extended them but then failed.  This really was the "last chance" Hail Mary and seemed to give some a reasonable extension and perhaps alleviated some of the pain or possible pain via metastices. We

[qwerty22]

An average of 8 cycles seems very high, higher than I've seen in other trials. Maybe it reflects the mix of different cancer types they were picking up.

[IFlyTheUnicorn]

This post has been removed in accordance with Community Policy